Eric Sievers - 31 Aug 2025 Form 4 Insider Report for BioAtla, Inc. (BCAB)

Reporting relationship: Chief Medical Officer
Issuer ticker: BCAB
Reported as of: 31 Aug 2025
Net transaction value: -$1,243
SEC form: 4
Accepted by SEC: 02 Sep 2025, 19:08:14 UTC
Prior SEC filing: 03 Jun 2025
Next SEC filing: 01 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Christian Vasquez, as Attorney-in-Fact for Eric Sievers

Key filing fact

Eric Sievers filed Form 4 for BioAtla, Inc. (BCAB) on 02 Sep 2025.

Key facts

This page summarizes Eric Sievers's Form 4 filing for BioAtla, Inc. (BCAB).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Sep 2025, 19:08.

Change

Previous filing in this sequence was filed on 03 Jun 2025.
Current net transaction value: -$1,243.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001835116 Primary reporting owner

Sievers Eric

Relationship: Chief Medical Officer
Address: C/O BIOATLA, INC. 11085 TORREYANA ROAD, SAN DIEGO
Signature: /s/ Christian Vasquez, as Attorney-in-Fact for Eric Sievers
Signature date: 02 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCAB transaction

Common Stock

Tax liability

Transaction value: $1,243
Shares: -2,729
Change %: -0.74%
Price: $0.4555
Shares after: 364,574
Date: 31 Aug 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.